Market closed
Sanofi/€SAN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Trading on
PAR
Industry
Pharmaceuticals
Headquarters
Employees
82,878
Website
Sanofi Metrics
BasicAdvanced
€111B
20.37
€4.44
0.46
€3.76
4.33%
Price and volume
Market cap
€111B
Beta
0.46
52-week high
€110.88
52-week low
€85.07
Average daily volume
2.6M
Dividend rate
€3.76
Financial strength
Current ratio
1.46
Quick ratio
0.28
Long term debt to equity
17.216
Total debt to equity
22.944
Dividend payout ratio (TTM)
84.60%
Interest coverage (TTM)
8.45%
Management effectiveness
Return on assets (TTM)
4.37%
Return on equity (TTM)
7.53%
Valuation
Price to earnings (TTM)
20.367
Price to revenue (TTM)
2.556
Price to book
1.47
Price to tangible book (TTM)
5.72
Price to free cash flow (TTM)
19.23
Dividend yield (TTM)
4.16%
Forward dividend yield
4.33%
Growth
Revenue change (TTM)
-3.80%
Earnings per share change (TTM)
6.75%
3-year revenue growth (CAGR)
4.17%
3-year earnings per share growth (CAGR)
-2.49%
3-year dividend per share growth (CAGR)
5.59%
What the Analysts think about Sanofi
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Sanofi Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sanofi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sanofi News
AllArticlesVideos
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
Reuters·3 days ago
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
GlobeNewsWire·3 days ago
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Market closed
Upcoming events
May12
Sanofi
Dividend·Ex-dividend
May14
Sanofi
Dividend·Payment
€3.92
Per share
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €111B as of April 21, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 20.37 as of April 21, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of April 21, 2025, the dividend rate is €3.76 and the yield is 4.33%. Sanofi has a payout ratio of 84.6% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment is scheduled for May 14, 2025.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.